Expand all sections

Valsartan / sacubitril

Entresto

Extended indication Chronic heart failure with preserved ejection fraction. Post-myocardial infarction, to reduce advers
Therapeutic value No judgement

Product

Active substance Valsartan / sacubitril
Domain Cardiovascular diseases
Main indication Heart failure
Extended indication Chronic heart failure with preserved ejection fraction. Post-myocardial infarction, to reduce adverse cardiac outcomes in patients with evidence of LV systolic dysfunction and/or pulmonary congestion.
Proprietary name Entresto
Manufacturer Novartis
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Fabrikant (nov 2017): Verwachte registratie HFpEF :2020, verwachte registratie MI: 2021

Registration

Registration route Centralised (EMA)
Expected Registration 2020
Orphan drug No
Additional remarks Indicatie-uitbreiding

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found
Frequency of administration 2 times a day

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost > 1,900.00
References Medicijnkosten.nl
Additional remarks € 2,62 per tablet. Voor behandeling op jaarbasis: €1915,02.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.